1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19324
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHanauske, A. R.en
dc.contributor.authorCatimel, G.en
dc.contributor.authorAamdal, S.en
dc.contributor.authorten Bokkel Huinink, W.en
dc.contributor.authorParidaens, R.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorKaye, S. B.en
dc.contributor.authorte Velde, A.en
dc.contributor.authorWanders, J.en
dc.contributor.authorVerweij, J.en
dc.date.accessioned2015-11-24T18:58:56Z-
dc.date.available2015-11-24T18:58:56Z-
dc.identifier.issn0007-0920-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19324-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibiotics, Antineoplastic/adverse effects/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapyen
dc.subjectFemaleen
dc.subjectHematopoiesis/drug effectsen
dc.subjectHumansen
dc.subjectLactones/adverse effects/therapeutic useen
dc.subjectMacrolidesen
dc.subjectMaleen
dc.subjectMelanoma/*drug therapyen
dc.subjectMiddle Ageden
dc.titlePhase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Groupen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8562349-
heal.identifier.secondaryhttp://www.nature.com/bjc/journal/v73/n3/pdf/bjc199668a.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1996-
heal.abstractRhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determine the clinical activity of this compound in patients with advanced breast cancer and melanoma. Based on the results of a phase I study, 2.0 mg m-2 was administered as intravenous infusion over 5 min every 21 days. Nineteen patients were entered into the breast cancer phase II trial and received a total of 50 courses (median 2, range 1-6). Of these, dose reductions were performed in three courses because of leucopenia or stomatitis (1.5 mg m-2, one course; 1.45 mg m-2, two courses). Twenty-six patients were entered into the melanoma trial and received a total of 70 courses (median 2, range 1-12). No dose reductions were required. All patients were eligible for toxicity. Haematological toxicity included neutropenia CTC grade 3 (29/120 courses, 24.2%) and grade 4 (11/20 courses, 9.2%). Only drug-related CTC grade 1 thrombocytopenia was observed. Non-haematological toxicity included alopecia in all patients after two courses of treatment as well as CTC grade 3/4 stomatitis and asthenia. In the breast cancer study, one patient achieved a more than 50% tumour reduction after six cycles but was progressing after 6 weeks. Another patient showed a partial remission after the first course but was taken off the study because of CTC grade 3 skin toxicity. One patient was not evaluable for response (early death). No objective remissions were observed in 15 evaluable patients. In melanoma, no objective remissions were observed. We conclude that rhizoxin can be safely administered at 2.0 mg m-2 every 3 weeks. However, it has little activity in patients with advanced breast cancer and melanoma.en
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Hanauske-1996-Phase II clinical tr.pdf603.14 kBAdobe PDFView/Open
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons